Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 209-217 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Viral status

  • Per Ljungman, MD, PhD (Professor, Head)

      Affiliations

    • Corresponding Author InformationTel.: +46 8 58582507; Fax: +46 8 7748725.

References 

  1. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. The New England Journal of Medicine. 1986;314(16):1006–1010
  2. Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scandinavian Journal of Infectious Diseases. 2002;34(5):347–350
  3. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. The Journal of Infectious Diseases. 2002 Feb 1;185(3):273–282
  4. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95(7):2240–2245
  5. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematology. 2001;112(1):228–236
  6. Meijer E, Dekker AW, Rozenberg-Arska M, et al. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clinical Infectious Diseases. 2002 Sep 15;35(6):703–712
  7. Ljungman P, Einsele H, Frassoni F, et al. Donor CMV serological status influences the outcome of CMVseropositive recipients after unrelated donor stem cell transplantation: an EBMT Megafile analysis. Blood. 2003;102:4255–4260
  8. Ringdén O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biology of Blood and Marrow Transplantation. 2004 Feb;10(2):128–134
  9. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001 Oct 1;98(7):2043–2051
  10. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004 Mar 15;103(6):2003–2008
  11. Fries BC, Riddell SR, Kim HW, et al. Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. Biology of Blood and Marrow Transplantation. 2005 Feb;11(2):136–148
  12. Cray C, Levy RB. Evidence that donor cells are present in the thymus of recipients undergoing a P→F1 graft-versus-host reaction exacerbated by concurrent murine cytomegalovirus infection. Transplantation. 1992 Mar;53(3):696–699
  13. Via CS, Shanley JD, Shearer GM. Synergistic effect of murine cytomegalovirus on the induction of acute graft-vs-host disease involving MHC class I differences only. Analysis of in vitro T cell function. Journal of Immunology. 1990 Nov 15;145(10):3283–3289
  14. Jones M, Cray C, Levy RB. Concurrent MCMV infection augments donor antihost-specific activity and alters clinical outcome following experimental allogenic bone marrow transplantation. Transplantation. 1996 Mar 27;61(6):856–861
  15. Bostrom L, Ringdén O, Forsgren M. Strong donor mononuclear cell reactivity for herpes simplex virus (HSV) antigen in HSV immune donors combined with recipient seropositivity for HSV is associated with acute graft-versus-host disease. Scandinavian Journal of Immunology. 1991 Jul;34(1):45–52
  16. Gratama JW, Zwaan FE, Stijnen T, et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet. 1987 Feb 28;1(8531):471–474
  17. Bostrom L, Ringdén O, Gratama JW, et al. The impact of pretransplant herpesvirus serology on acute and chronic graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Transplantation Proceedings. 1990 Feb;22(1):206–207
  18. Jacobsen N, Andersen HK, Skinhoj P, et al. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scandinavian Journal of Haematology. 1986 May;36(5):499–506
  19. Ljungman P, Niederwieser D, Pepe MS, et al. Cytomegalovirus infection after marrow transplantation for aplastic anemia. Bone Marrow Transplantation. 1990;6(5):295–300
  20. Söderberg C, Larsson S, Rozell BL, et al. Cytomegalovirus-induced CD13-specific autoimmunity – a possible cause of chronic graft-vs-host disease. Transplantation. 1996;61(4):600–609
  21. Söderberg C, Sumitran KS, Ljungman P, et al. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation. 1996;61(4):594–600
  22. Nichols WG, Boeckh M, Carter RA, et al. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. The Journal of Infectious Diseases. 2003 Mar 1;187(5):801–808
  23. Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation – a randomized double-blind placebo-controlled study. Blood. 2006 Mar 1;107(5):1800–1805
  24. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clinical Infectious Diseases. 2001;33(supplement 1):S38–S46
  25. Sundin M, LeBlanc K, Ringdén O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(8):1059–1068
  26. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clinical Infectious Diseases. 2004 Sep 1;39(5):673–680
  27. Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplantation. 2001 Jul;28(1):51–57
  28. Sora F, Antinori A, Piccirillo N, et al. Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia. Experimental Hematology. 2002 Mar;30(3):279–284
  29. Kang EM, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood. 2002 Jan 15;99(2):698–701
  30. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005 May;19(5):829–834
  31. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. British Journal of Haematology. 2003 Jan;120(2):304–309
  32. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005 May 15;105(10):4143–4145
  33. Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. International Journal of Hematology. 2002 Jul;76(1):91–93
  34. Ljungman P, Lawler M, Asjo B, et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. British Journal of Haematology. 1994 Oct;88(2):403–405
  35. Kikuchi H, Ohtsuka E, Ono K, et al. Allogeneic bone marrow transplantation-related transmission of human T lymphotropic virus type I (HTLV-I). Bone Marrow Transplantation. 2000 Dec;26(11):1235–1237
  36. Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. The New England Journal of Medicine. 2006 Apr 20;354(16):1758–1759
  37. Brenner W, Storch G, Buller R, et al. West Nile virus encephalopathy in an allogeneic stem cell transplant recipient: use of quantitative PCR for diagnosis and assessment of viral clearance. Bone Marrow Transplantation. 2005 Aug;36(4):369–370
  38. Hiatt B, DesJardin L, Carter T, et al. A fatal case of West Nile virus infection in a bone marrow transplant recipient. Clinical Infectious Diseases. 2003 Nov 1;37(9):e129–e131
  39. Hong DS, Jacobson KL, Raad , et al. West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clinical Infectious Diseases. 2003 Oct 15;37(8):1044–1049
  40. Robertson KB, Barron MA, Nieto Y. West Nile virus infection in bone marrow transplant patients. Bone Marrow Transplantation. 2004 Nov;34(9):823–824

PII: S1521-6926(06)00063-6

doi: 10.1016/j.beha.2006.09.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 209-217 , June 2007

Article Tools